Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference
CARLSBAD, Calif., Nov. 10, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc., I (NASDAQ: IONS) announced today that accomplished Ionis scientists will highlight the company's pioneering advancements in research and drug development in antisense technology during the RNA at the Bench and Bedside II Conference, to be held virtually Nov. 11-13, 2020. Plenary session presentations will include a review of the cardiovascular Phase 3 clinical trials Lp(a) HORIZON evaluating pelacarsen and CARDIO-TTRansform evaluating AKCEA-TTR-LRx; updates on how medicines developed using Ionis' advanced LIgand-Conjugated Antisense (LICA) technology are showing promise as potential treatments for heart failure and metabolic diseases; and a discussion on technology advances in the delivery of antisense medicines, including oral and aerosol administration.
More than 30 speakers from across industry and academia will present at the conference, which is sponsored by Ionis, University of California San Diego School of Medicine, Nature Biotechnology and Nature Structural & Molecular Biology. The conference was inspired by Ionis founder and executive chairman of the board Stanley T. Crooke, M.D., Ph.D., who pioneered antisense technology and RNA-targeted therapeutics more than 30 years ago.
"As the leader in RNA-targeted therapeutics, Ionis is excited to participate in the RNA at the Bench and Bedside II Conference, which this year emphasizes clinical advances in cardiovascular and metabolic diseases. Ionis has established vast experience in cardio-metabolic diseases and this, along with many breakthrough advances in our technology, have created a rich pipeline of potential first-in-class medicines to treat a wide range of cardio-metabolic diseases with significant unmet medical need," said Brett P. Monia, Ph.D., Ionis' chief executive officer.
Following are Ionis presentations scheduled for the conference:
In addition to plenary sessions, numerous posters by Ionis scientists will be presented during the conference:
Ionis collaborators and partners will also present on Ionis research and clinical development stage programs during the conference:
About Ionis Pharmaceuticals, Inc.
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for all patients, children and adults with spinal muscular atrophy, as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to potentially treat a broad range of disease, including neurological, cardio-renal, metabolic, infectious, and pulmonary diseases.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ionis-antisense-technology-to-be-featured-during-virtual-rna-at-the-bench-and-bedside-ii-conference-301169264.html
SOURCE Ionis Pharmaceuticals, Inc.
Company Codes: NASDAQ-NMS:IONS